End-Stage Renal Disease Clinical Trial
Official title:
An Interventional Trial in Established Chronic Renal Allograft Rejection
The purpose of this study is to see how effective 2 drugs, irbesartan and pravastatin, are
at slowing kidney transplant failure.
Many kidney transplant patients have some type of chronic rejection. Chronic rejection is a
disease that causes scarring and damage to the kidney. Over time, chronic rejection can lead
to kidney failure, making it necessary for patients to start dialysis and possibly receive
another kidney transplant. Doctors would like to see whether irbesartan and pravastatin can
slow this damage and prevent kidney failure in patients with signs of chronic rejection.
Status | Completed |
Enrollment | 0 |
Est. completion date | March 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria You may be eligible for this study if you: - Are at least 18 years old. - Received a kidney transplant at least 1 year prior to study entry. - Have been diagnosed with chronic rejection following kidney transplant and within 6 months prior to study entry. - Have been receiving a stable immunosuppressive medication regimen for 1 month prior to study entry that includes at least cyclosporine or tacrolimus and prednisone. - Have high blood pressure. - Agree to use an effective method of birth control during the study. Exclusion Criteria You will not be eligible for this study if you: - Are participating in another study with required tests or treatments. - Cannot take ACE inhibitors or HMG-CoA reductase inhibitors. - Absolutely must take ACE inhibitors or HMG-CoA reductase inhibitors. - Have a serious disease or medical condition. - Are pregnant. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Ilene Blechman-Krom | Rockville | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | death, or renal failure manifested by initiation of dialysis or retransplantation. | Randomization to End of Study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCareā¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A |